Fig. 6: LC-FACSeq can track mutations in leukemia stem cell (LSC) and non-LSC compartments of AML patients at diagnosis, remission and relapse. | Leukemia

Fig. 6: LC-FACSeq can track mutations in leukemia stem cell (LSC) and non-LSC compartments of AML patients at diagnosis, remission and relapse.

From: Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq

Fig. 6

A Fish plots represent the clonal evolution of AML that can be inferred from the variant allelic frequencies (VAF) of somatic mutations detected with LC-FACSeq, which are shown in the corresponding graphs of paired diagnosis and relapse samples. The mutational composition of LSC compartment is also illustrated. B Monitorization of TP53 mutation in patient AML-11 at serial diagnosis, remission and relapse samples. Dx diagnosis, CR complete remission, HDAC high-dose cytarabine, IDAC intermediate-dose cytarabine; 7 + 3 (7-days of cytarabine and 3-days of daunorubicin).

Back to article page